Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Rosuvastatin and Ezetimibe Combination in Primary Hypercholesterolemia
NCT03571087Phase 3Completed
- Sponsor
- Hanlim Pharm
- Start
- Sep 2014
- Primary completion
- Aug 2015
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of ezetimibe + rosuvastatin in hypercholesterolemia (6 arms), sponsored by Hanlim Pharm. Primary endpoint: Percentage change in LDL-Cholesterol from baseline at 8 weeks. Started Sep 2014; status: completed.
02
Drugs
ezetimibe + rosuvastatin
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT03571087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03571087.